Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease. Issue 6 (18th August 2017)

• Record Type: Journal Article
• Authors: Vandesquille, Matthias; Li, Tengfei; Po, Chrystelle; Ganneau, Christelle; Lenormand, Pascal; Dudeffant, Clémence; Czech, Christian; Grueninger, Fiona; Duyckaerts, Charles; Delatour, Benoît; Dhenain, Marc; Lafaye, Pierre; Bay, Sylvie
• Is Part Of: MAbs. Volume 9:Issue 6(2017)
• Page Start: 1016
• Page End: 1027
• Publication Date: 2017-08-18
• Subjects: Alzheimer's disease diagnosis -- amyloid deposits -- chemically-defined imaging probe -- magnetic resonance imaging -- single-domain antibody -- site-specific conjugation; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1342914
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Today, molecular imaging of neurodegenerative diseases is mainly based on small molecule probes. Alternatively, antibodies are versatile tools that may be developed as new imaging agents. Indeed, they can be readily obtained to specifically target any antigen of interest and their scaffold can be functionalized. One of the critical issues involved in translating antibody-based probes to the clinic is the design and synthesis of perfectly-defined conjugates. Camelid single-domain antibody-fragments (VHHs) are very small and stable antibodies that are able to diffuse in tissues and potentially cross the blood brain barrier (BBB). Here, we selected a VHH (R3VQ) specifically targeting one of the main lesions of Alzheimer's disease (AD), namely the amyloid-beta (Aß) deposits. It was used as a scaffold for the design of imaging probes for magnetic resonance imaging (MRI) and labeled with the contrastophore gadolinium using either a random or site-specific approach. In contrast to the random strategy, the site-specific conjugation to a single reduced cysteine in the C -terminal part of the R3VQ generates a well-defined bioconjugate in a high yield process. This new imaging probe is able to cross the BBB and label Aß deposits after intravenous injection. Also, it displays improved r1 and r2 relaxivities, up to 30 times higher than a widely used clinical contrast agent, and it allows MRI detection of amyloid deposits in post mortem brain tissue of a mouse model of AD. The ability to produce chemically-defined VHH conjugates that cross the BBB opens the way for future development of tailored imaging probes targeting intracerebral antigens.